Binghe Xu
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Emerging Leaders
not ranked
Current Leaders
#4540 pts
All-Time Leaders
#15540 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2010. 9 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase 2 Clinical Trial:Low -Dose-bevacizumab and Pemetrexed Versus Treatment of Physician's Choice in Metastatic HER2-negative Breast Cancer Patients After Failure of Taxanes and Anthracycline-containing Regimens
Phase 2UnknownChinese Academy of Medical Sciences
7
impact
A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice
N/ATerminatedAstraZeneca
6
impact
A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.
Phase 3UnknownChinese Academy of Medical Sciences
4
impact
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
N/AUnknownChinese Academy of Medical Sciences
3
impact
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR-positive and HER2-negative Advanced Breast Cancer
Phase 3UnknownAhon Pharmaceutical Co., Ltd.
3
impact
Phase 3 Study of Regimens Comparison for Breast Cancers of Positive Lymph Nodes
Phase 3UnknownChinese Academy of Medical Sciences
3
impact
A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer
Phase 3UnknownBinghe Xu
2
impact
Phase I Clinical Trial on Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
Phase 1UnknownBeijing Biostar Pharmaceuticals Co., Ltd.
2
impact
A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial of GB491 Combined With Fulvestrant in Subjects With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy
Phase 3CompletedGenor Biopharma Co., Ltd.
2
impact
A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer
Phase 3ActiveXuanzhu Biopharmaceutical Co., Ltd.
2
impact
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
Early Ph 1RecruitingShanghai Pharmaceuticals Holding Co., Ltd
2
impact
Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
Phase 3UnknownChinese Academy of Medical Sciences
1
impact
The Efficacy and Safety of Pyrotinib Combined With Etoposide in HER2-positive Advanced Breast Cancer
Phase 2UnknownChinese Academy of Medical Sciences
1
impact
Efficacy and Safety Phase IIb Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Breast Cancer Patients
Phase 2CompletedTianjin SinoBiotech Ltd.
1
impact
The Efficacy and Safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer :Single Arm, Phase II Clinical Trail
Phase 2UnknownChinese Academy of Medical Sciences
1
impact
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study
Phase 3UnknownChinese Academy of Medical SciencesStudy Chair
0
impact
A Phase Ib/IIa, Open-Label, Two-Cohort, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) Who Have Progressed After First-Line or Later-Line Therapy
Phase 2RecruitingShenzhen Majory Biotechnology Co., Ltd.
0
impact
A Phase I/II, Open-Label, Non-Randomized, Multi-Centre First-in-Human Study of CAN016 in Patients With Advanced Solid Tumors
Phase 1Not Yet RecruitingCanwell Biotech Limited
0
impact
A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S in Breast Cancer Patients With Leptomeningeal Metastases, With or Without Brain Parenchymal Metastases
Phase 2RecruitingNantong Bencao Quadriga Medical Technology Co. Ltd.
0
impact
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer After Failure of at Least One Prior Line of Chemotherapy
Phase 3ActiveSichuan Baili Pharmaceutical Co., Ltd.
0
impact
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics or Preliminary Efficacy and Antitumor Activity of GNC-077 Multi-specific Antibody Injection in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
0
impact
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer: an Exploratory, Single-arm, Multi-center Trial
Phase 4Not Yet RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
N/AUnknownCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Multicenter, Open-label, Randomized Controlled Phase III Clinical Study to Compare the Efficacy and Safety of FS-1502 Versus T-DM1 in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 3UnknownShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
0
impact
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 in Advanced Solid Tumor Patients
Phase 1UnknownBetta Pharmaceuticals Co., Ltd.
0
impact
0
impact
Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer: Single Arm, Single Center, Phase II Clinical Trial.
Phase 2UnknownChinese Academy of Medical Sciences
0
impact
An Open, Multicenter Study for the Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
N/AUnknownChinese Academy of Medical Sciences
0
impact
Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
Phase 2UnknownCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Phase I Open and Multiple Ascending Dose Study to Assess the Safety、Tolerability、Pharmacokinetics and Pharmacodynamic Characteristics of XY0206 in Subjects With Chinese Advanced or Metastatic Solid Tumours
Phase 1UnknownShijiazhuang Yiling Pharmaceutical Co. Ltd
0
impact
Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy. - an Open , Multicenter, Non-interventional Clinical Trial
N/AUnknownChinese Academy of Medical Sciences
0
impact
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
Phase 1CompletedRemeGen Co., Ltd.
0
impact
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer: a Phase 2, Prospective,Multicenter, Randomised Study
Phase 2UnknownChinese Academy of Medical Sciences
0
impact
Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients
Phase 2UnknownChinese Academy of Medical Sciences
0
impact
A Phase II, Single-arm, Multicenter Study of Etoposide Monotherapy in Treating Patients With Recurrent or Metastatic Breast Cancer
Phase 2UnknownChinese Academy of Medical Sciences
0
impact
An Open-label, Single-arm, Multicenter, Phase II Study to Assess the Efficacy and Safety of Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule) as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer
Phase 2UnknownChinese Academy of Medical Sciences
0
impact
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
Phase 4CompletedChinese Academy of Medical SciencesStudy Chair
0
impact